It was not that long after Deborah Dunsire took hold of the reins at Lundbeck Inc. that she knew she had a tough job on her hands. Strategic cost-cutting decisions by the previous ceo Kare Schultz, he left to join Teva Pharmaceutical Industries Ltd., had steadied the ship financially but the impending loss of exclusivity of the company’s best-selling drug, Onfi, the epilepsy treatment, was always going to be a major challenge.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?